1. Home
  2. Analysis
  3. Sennosides
  4. Phenergan

Sennosides and Phenergan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Sennosides (senna) and Phenergan (promethazine hydrochloride). Common drug interactions include hypertension among females and atrial fibrillation among males.

The phase IV clinical study analyzes what interactions people have when they take Sennosides and Phenergan. It is created by eHealthMe based on reports of 28 people who take the same drugs from the FDA, and is updated regularly.

What is Sennosides?

Sennosides has active ingredients of senna. It is often used in constipation. eHealthMe is studying from 8,247 Sennosides users. Check the latest studies of Sennosides.

What is Phenergan?

Phenergan has active ingredients of promethazine hydrochloride. It is often used in nausea. eHealthMe is studying from 25,312 Phenergan users. Check the latest studies of Phenergan.

On Jul, 20, 2026

28 people who take Sennosides and Phenergan together, and have interactions are studied.

Sennosides and Phenergan drug interactions.

What are the common drug interactions of Sennosides and Phenergan, by gender? *:

female:

  1. Hypertension (high blood pressure)
  2. Pyrexia (fever)
  3. Asthenia (weakness)
  4. Chills (felling of cold)
  5. Dizziness
  6. Fatigue (feeling of tiredness)
  7. Headache (pain in head)
  8. Influenza
  9. Pain
  10. Abdominal pain lower

male:

  1. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  2. Malaise (a feeling of general discomfort or uneasiness)
  3. Anxiety
  4. Chronic kidney disease
  5. Emergency care
  6. Metabolic encephalopathy (disorder or disease of the brain due to the body's disability to use energy)
  7. Renal failure (kidney dysfunction)
  8. Suicidal ideation
  9. Therapeutic response unexpected
  10. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)

What are the common drug interactions of Sennosides and Phenergan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Anxiety
  2. Emergency care
  3. Metabolic encephalopathy (disorder or disease of the brain due to the body's disability to use energy)
  4. Suicidal ideation
  5. Therapeutic response unexpected

20-29:

n/a

30-39:

  1. Chronic kidney disease
  2. Renal failure (kidney dysfunction)

40-49:

  1. Oral pain
  2. Chronic kidney disease
  3. Hyperkalaemia (damage to or disease of the kidney)
  4. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  5. Nephrogenic anaemia (anaemia due to kidney disease)
  6. Neutropenia (an abnormally low number of neutrophils)
  7. Platelet count decreased
  8. Renal failure (kidney dysfunction)
  9. Renal tubular necrosis (death of kidney tubules)

50-59:

  1. Asthenia (weakness)
  2. Abdominal pain lower
  3. Alanine aminotransferase increased
  4. Aspartate aminotransferase increased
  5. Blood alkaline phosphatase increased
  6. Cardiomegaly (increased size of heart than normal)
  7. Chest pain
  8. Chills (felling of cold)
  9. Dizziness
  10. Dyspnoea (difficult or laboured respiration)

60+:

  1. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  2. Malaise (a feeling of general discomfort or uneasiness)
  3. Hepatic failure (liver failure)
  4. Herpes zoster
  5. Human papilloma virus test positive
  6. Hypertension (high blood pressure)
  7. Infusion related reaction
  8. Migraine (headache)
  9. Nodule (a growth of abnormal tissue)
  10. Pain

What are the existing conditions these people have? *

  1. Depression: 7 people, 25.00%
  2. Enlarged Prostate: 7 people, 25.00%
  3. Fever: 6 people, 21.43%
  4. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 6 people, 21.43%
  5. Blood Testosterone Decreased: 6 people, 21.43%
  6. Cardiomyopathy (weakening of the heart muscle): 6 people, 21.43%
  7. Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 6 people, 21.43%
  8. Lymphoma (cancer that begins in immune system cells): 5 people, 17.86%
  9. Pulmonary Hypertension (increase in blood pressure in the lung artery): 5 people, 17.86%
  10. Muscle Spasms (muscle contraction): 5 people, 17.86%

* Approximation only. Some reports may have incomplete information.

Do you take Sennosides and Phenergan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Sennosides and Phenergan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Sennosides:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Phenergan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Sennosides and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Phenergan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on senna and promethazine hydrochloride (the active ingredients of Sennosides and Phenergan, respectively), and Sennosides and Phenergan (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.